Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

FORTMYL GRANULADO PARA SOLUCION ORAL EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/FORTMYL GRANULADO PARA SOLUCION ORAL EFG

Approved

STANDARD

FORTMYL GRANULADO PARA SOLUCION ORAL EFG

Viamoalta S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 4, 2024
Approval ID: e548ee2a9ebe5437
Company: Viamoalta S.L.
Type: Standard

Approval Details

Approval Id: e548ee2a9ebe5437
Drug Cima Aemps Name: FORTMYL GRANULADO PARA SOLUCION ORAL EFG
Register Number: 89681
Holder Company Name: Viamoalta S.L.
Marketing Company Name: Viamoalta S.L.
Authorization Date: 2024-07-04
Dosage Form: GRANULADO PARA SOLUCIÓN ORAL
Dose: 650 mg/15,58 mg/4 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: No
Company Name: Viamoalta S.L.

Active Ingredients

PARACETAMOL

650 mg

FENILEFRINA BITARTRATO

15,58 mg

CLORFENAMINA MALEATO

4 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 4, 2024

Approval ID

e548ee2a9ebe5437

Type

Standard

Back to CIMA-AEMPS Approvals